What is AviadoBio?
Founded in 2019 and headquartered in London, AviadoBio operates at the intersection of advanced genetic medicine and neurology. The company is dedicated to the development of transformative gene therapies designed to treat debilitating neurological diseases that currently lack effective therapeutic interventions. By leveraging sophisticated delivery mechanisms and precision genetic engineering, AviadoBio is positioning itself as a key player in the European biotechnology landscape, aiming to translate complex scientific research into viable clinical solutions for patients with high unmet medical needs.
How much funding has AviadoBio raised?
AviadoBio has raised a total of $80M across 1 funding round:
Series A
$80M
Series A (2021): $80M with participation from Monograph Capital and New Enterprise Associates
Key Investors in AviadoBio
Monograph Capital
A specialized investment firm focused on the life sciences sector, providing strategic support to companies developing innovative therapeutic platforms.
New Enterprise Associates
Established in 1977 and headquartered in Menlo Park, California. New Enterprise Associates(NEA) is a venture capital firm focused on helping entrepreneurs build businesses.
What's next for AviadoBio?
Following this major strategic investment, AviadoBio is expected to prioritize the advancement of its lead candidates through critical preclinical and early-stage clinical milestones. The infusion of capital will likely be deployed to expand internal research capabilities, enhance manufacturing processes for viral vector delivery, and bolster the talent pool required to navigate the rigorous regulatory pathways associated with gene therapy. As the company transitions from a research-focused entity to a clinical-stage organization, the focus will remain on demonstrating safety and efficacy in human trials, thereby de-risking the platform for future institutional partnerships or potential public market entry.
See full AviadoBio company page
